Route Of Administration Semaglutide: subcutaneous injection weekly
Rybelsus is a oncedaily oral tablet
"Finding new and better treatments is critically important to help people live healthier lives." References Nirupam M Srinivasan, Mehdi Farokhnia, Lisa A Farinelli, Anna Ferrulli, Lorenzo Leggio, GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer, Journal of the Endocrine Society , Volume 9, Issue 11, November 2025, bvaf141,

Based on analysis of employer experiences, vendor data, and expert interviews, PHTI outlines five key recommendations for employers: Establish clear, clinically driven eligibility pathways for GLP-1 coverage Require participation in behavior, nutrition, or lifestyle change programs as a condition of coverage Provide structured support for employees who choose to taper or discontinue GLP-1 therapy Review existing vendor capabilities before adding additional point solutions Contract with vendors to drive outcomes while examining overall program costs The report identifies three critical phases where these solutions can support employers in managing their GLP-1 coverage: Initiation: Providing targeted GLP-1 coverage using clinical criteria, behavioral or AI-based screening, narrow prescribing networks, or step-therapy pathways that include lower-cost alternatives or lifestyle change programs
Neuroprotective Potential One of the most exciting future applications
Any off-label use should be approached cautiously, ideally within clinical trials, and discussed thoroughly with healthcare providers